Financing for medtech stands at a respectable $208 million so far in the month of September, with an average deal size of $14.8 million.
OK, now take out one financing, Valeritas’ $150 million financing for its drug delivery technologies, and you have a different picture:
Financing for medtech stands at a paltry $58 million so far in the month of September, with an average deal size of $4.5 million. See the September 2011 medtech financings in detail at link.
It is therefore important to not simply dismiss outliers (see if Valeritas would dismiss $150 million), but recognize their impact on the results.